Clinical Trials · NCT04187300
A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 68
- Start date
- Dec 2019
- Locations
- 1 site, Germany
- Primary endpoint
- AUC0-168h,2.4mg,SS, Area under the semaglutide concentration time curve